Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
Participation advances the company’s vision and regulatory pathway for earlier intervention, screening for prediabetes and Type 2 diabetes and empowerment
Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722426337/en/ Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
Participation in the TEMPO pilot will allow Dexcom to implement an AI-powered glucose health program that integrates data from Dexcom G7 and Stelo with contextual health information such as nutrition, physical activity, sleep and stress, to deliver more personalized insights for healthcare professionals and program eligible users. The program leverages Dexcom's industry-leading clinician software platform, to provide healthcare professionals with a more comprehensive view of metabolic health, helping them monitor progress and personalize therapy at a population level. The program is also intended as an aid in the screening of prediabetes and Type 2 diabetes through integrated digital health metrics and may contribute to improving glycemic control and lowering HbA1c in people with prediabetes.
